Bionomics has a portfolio of well differentiated drug candidates.  Each target the treatment of serious conditions with significant unmet clinical need, and for which large market opportunities exist. We are able to not only sustain but accelerate our pipeline development by virtue of two distinguishing attributes:  1) high quality drug candidates and 2) our strategic partnering strategy which allows multiple and diverse programs to be optimally developed.